| Summary: | Wei Li,1 Huiqin Jiang,1 Yiyi Yu,1 Yan Wang,1 Zhiming Wang,1 Yuehong Cui,1 Kuntang Shen,2 Zhenbin Shen,2 Yong Fang,2 Tianshu Liu1,3 1Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China; 2Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; 3Center of Evidence-Based Medicine, Fudan University, Shanghai, China Purpose: Chemotherapy is the standard care for patients with incurable advanced gastric cancer. Whether or when the addition of gastrectomy to chemotherapy improves survival of advanced gastric cancer patients with a single noncurable factor remains controversial. We aimed to evaluate the superiority of gastrectomy following chemotherapy vs chemotherapy alone regarding overall survival (OS) in these patients.Patients and methods: Patients with advanced gastric cancer from January 2008 to December 2014 were retrieved from our prospectively acquired database and retrospectively analyzed. The patients with a single noncurable factor were grouped in terms of cancer treatment: chemotherapy alone or gastrectomy following chemotherapy.Results: Four hundred and fourteen patients (333 chemotherapy alone and 81 gastrectomy following chemotherapy) were included in this study. Kaplan–Meier survival curve showed a significant difference on median OS between chemotherapy-alone group and the gastrectomy plus chemotherapy group (10.9 vs 15.9 months, P<0.01). After propensity score analysis (n=126), chemotherapy plus surgery (81 patients) also showed survival benefit over chemotherapy alone (35 patients) (15.9 vs 10.0 months, P<0.01). Furthermore, stratified analyses indicated that patients with liver metastasis, Conclusion: This study suggests that gastrectomy after chemotherapy could lead to survival benefit over chemotherapy alone in advanced gastric cancer patients with a single nonresectable factor if the disease was controllable by chemotherapy. Keywords: gastric cancer, palliative surgery, overall survival, propensity score analysis
|
|---|
